Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrativ...(a Dr. Reshma Mahtani MD Anderson...),Health

Date:11/20/2008

a Dr. Reshma Mahtani MD Anderson, Houston, Texas Dr. Banu Arun Memorial Cancer Institute, Hollywood, Florida Dr. Alejandra Perez Montefiore Medical Center, Bronx, New York Dr. Tianhong Li Ohio State University, Columbus, Ohio Dr. Ewa Mrozek St. Vincent's Medical Center, New York, New York Dr. Paula Klein University of California, San Francisco, California Dr. Hope Rugo University of Chicago, Chicago, Illinois Dr. Gini Fleming University of Miami, Miami, Florida Dr. Alberto Montero University of Pittsburg Magee Women's Hospital, Pittsburg, Pennsylvania Dr. Adam Brufsky University of Southern California, Los Angeles, California Dr. Agustin Garcia University of Texas, Southwestern, Dallas, Texas Dr. Jenny Li

BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. BZL101 stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain unharmed.

There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are s
'/>"/>

SOURCE Bionovo, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium